BR112022011122A2 - Epítopos e anticorpos de trpv1 - Google Patents

Epítopos e anticorpos de trpv1

Info

Publication number
BR112022011122A2
BR112022011122A2 BR112022011122A BR112022011122A BR112022011122A2 BR 112022011122 A2 BR112022011122 A2 BR 112022011122A2 BR 112022011122 A BR112022011122 A BR 112022011122A BR 112022011122 A BR112022011122 A BR 112022011122A BR 112022011122 A2 BR112022011122 A2 BR 112022011122A2
Authority
BR
Brazil
Prior art keywords
antibodies
trpv1
epitopes
relates
immunoconjugates
Prior art date
Application number
BR112022011122A
Other languages
English (en)
Inventor
Trkulja Carolina
Davidson Max
Orwar Owe
Original Assignee
Oblique Therapeutics Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oblique Therapeutics Ab filed Critical Oblique Therapeutics Ab
Publication of BR112022011122A2 publication Critical patent/BR112022011122A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

EPÍTOPOS E ANTICORPOS DE TRPV1. A presente invenção se refere a anticorpos que se ligam a TRPV1. A invenção também se refere a certos epítopos do TRPV1 de proteína. A invenção também se refere a imunoconjugados e composições que compreendem tais anticorpos. A invenção também fornece métodos de produção de tais anticorpos. A invenção fornece adicionalmente o uso de tais anticorpos para propósitos terapêuticos, por exemplo, no tratamento de dor.
BR112022011122A 2019-12-10 2020-12-10 Epítopos e anticorpos de trpv1 BR112022011122A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1918103.1A GB201918103D0 (en) 2019-12-10 2019-12-10 Epitopes and antibodies
PCT/EP2020/085629 WO2021116341A1 (en) 2019-12-10 2020-12-10 Trpv1 epitopes and antibodies

Publications (1)

Publication Number Publication Date
BR112022011122A2 true BR112022011122A2 (pt) 2022-09-06

Family

ID=69172152

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022011122A BR112022011122A2 (pt) 2019-12-10 2020-12-10 Epítopos e anticorpos de trpv1

Country Status (13)

Country Link
US (1) US20230322916A1 (pt)
EP (1) EP4073118A1 (pt)
JP (1) JP2023506433A (pt)
KR (1) KR20220123240A (pt)
CN (1) CN115244083A (pt)
AU (1) AU2020403105A1 (pt)
BR (1) BR112022011122A2 (pt)
CA (1) CA3159521A1 (pt)
GB (1) GB201918103D0 (pt)
IL (1) IL293641A (pt)
MX (1) MX2022006941A (pt)
WO (1) WO2021116341A1 (pt)
ZA (1) ZA202205813B (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202019522D0 (en) * 2020-12-10 2021-01-27 Oblique Therapeutics Ab Epitopes and antibodies

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990010457A1 (en) 1989-03-14 1990-09-20 New York University Method of treating hiv infections using immunotoxins
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
ES2241710T3 (es) 1991-11-25 2005-11-01 Enzon, Inc. Procedimiento para producir proteinas multivalentes de union a antigeno.
WO1999009140A1 (en) * 1997-08-20 1999-02-25 The Regents Of The University Of California Nucleic acid sequences encoding capsaicin receptor and capsaicin receptor-related polypeptides and uses thereof
JP2003520022A (ja) * 1999-04-15 2003-07-02 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド ヒトのバニロイドレセプターｖｒ１をコードするｄｎａ
GB201617002D0 (en) * 2016-10-06 2016-11-23 Oblique Therapeutics Ab Multi-protease method

Also Published As

Publication number Publication date
CN115244083A (zh) 2022-10-25
EP4073118A1 (en) 2022-10-19
KR20220123240A (ko) 2022-09-06
GB201918103D0 (en) 2020-01-22
CA3159521A1 (en) 2021-06-17
WO2021116341A1 (en) 2021-06-17
ZA202205813B (en) 2023-10-25
US20230322916A1 (en) 2023-10-12
AU2020403105A1 (en) 2022-06-16
JP2023506433A (ja) 2023-02-16
IL293641A (en) 2022-08-01
MX2022006941A (es) 2022-09-29

Similar Documents

Publication Publication Date Title
CY1124771T1 (el) Αντισωματα εναντι-σορτιλiνης και μεθοδοι χρησης αυτων
CY1122840T1 (el) Ανθρωποποιημενα ή χιμαιρικα αντισωματα cd3
MX2022004072A (es) Anticuerpos de factor xi y metodos de uso.
ZA202006859B (en) Antibodies specific for gucy2c and uses thereof
BR112021019334A2 (pt) Anticorpos de cadeia pesada que se ligam ao psma
EA201790342A1 (ru) Антитела к trem2 и способы их применения
PH12019501387A1 (en) Anti-cd3 antibody and molecules comprising the antibody
MD3463435T2 (ro) Anticorpi impotriva alfa sinucleinei și utilizări ale acestora
GT201200318A (es) Anticuerpos hacia gdf8 humano
AR080685A1 (es) Composiciones de anticuerpos anti-factor de crecimiento nervioso (ngf)
BR112019024654A2 (pt) proteína de ligação nkg2d, cd16 e ror1 ou ror2
BR112019017403A2 (pt) composições e métodos para o tratamento de câncer
BR112021024956A2 (pt) Anticorpos multiespecíficos de cadeia pesada que se ligam a cd22 e cd3
CY1124922T1 (el) Καινοτομος σταθερη φαρμακοτεχνικη μορφη για αντισωματα fxia
BR112018072681A2 (pt) anticorpos anti-il-1r3 humanizados
BR112022016643A2 (pt) Epítopos e anticorpos contra kras
EA202092085A1 (ru) ТЕРАПЕВТИЧЕСКИЕ АНТИТЕЛА ПРОТИВ sPLA2-GIB И ИХ ПРИМЕНЕНИЕ
CL2019001749A1 (es) Uso de anticuerpos anti-esclerostina en el tratamiento de osteogenesis imperfecta.
EA202190235A1 (ru) Антитела к cd33 и способы их применения
MX2019009498A (es) Anticuerpos mimeticos de fgf21 y usos de los mismos.
MX2021006362A (es) Anticuerpos de dominio simple contra cll-1.
MX2021005085A (es) Formulacion de anticuerpo.
BR112022008756A2 (pt) Conjugados anticorpo-fármaco anti-mesotelina eribulina e métodos de uso
EA202191769A1 (ru) Тубулизины и конъюгаты белок-тубулизин
EA202190183A1 (ru) Антитела к siglec-5 и способы их применения